High-throughput screens (HTS) of compound toxicity against cancer cells can identify thousands of potential new drug-leads. But only limited numbers of these compounds can progress to expensive and labor-intensive efficacy studies in mice, creating a 'bottle neck' in the drug development pipeline. Approaches that triage drug-leads for further study are greatly needed. Here we provide an intermediary platform between HTS and mice by adapting mouse models of pediatric brain tumors to grow as orthotopic xenografts in the brains of zebrafish. Freshly isolated mouse ependymoma, glioma and choroid plexus carcinoma cells expressing red fluorescence protein were conditioned to grow at 34°C. Conditioned tumor cells were then transplanted orthotopically into the brains of zebrafish acclimatized to ambient temperatures of 34°C. Live in vivo fluorescence imaging identified robust, quantifiable and reproducible brain tumor growth as well as spinal metastasis in zebrafish. All tumor xenografts in zebrafish retained the histological characteristics of the corresponding parent mouse tumor and efficiently recruited fish endothelial cells to form a tumor vasculature. Finally, by treating zebrafish harboring ERBB2-driven gliomas with an appropriate cytotoxic chemotherapy (5-fluorouracil) or tyrosine kinase inhibitor (erlotinib), we show that these models can effectively assess drug efficacy. Our data demonstrate, for the first time, that mouse brain tumors can grow orthotopically in fish and serve as a platform to study drug efficacy. As large cohorts of brain tumor-bearing zebrafish can be generated rapidly and inexpensively, these models may serve as a powerful tool to triage drug-leads from HTS for formal efficacy testing in mice.
INTRODUCTION
Brain tumors include the most lethal forms of childhood cancer, but few new treatments of these diseases have been developed during the last 30 years. 1 This impasse has resulted, in part, from a lack of disease models that can be used in preclinical highthroughput screens (HTS) and drug efficacy testing. Recently, our group and others have developed accurate mouse models of pediatric medulloblastoma, [2] [3] [4] [5] glioma, 6 ependymoma 7 and choroid plexus carcinoma. Together, these models represent >60% of childhood brain tumors and therefore have great potential to assist discovery of new therapies for all patients. Development of the smoothened inhibitor vismodegib for the treatment of SHHsubtype medulloblastoma using the Ptch +/− ;Tp53 −/ − mouse model provides proof-of-principle of this approach. 8 We have also shown that mouse brain tumor models can be used in HTS campaigns; identifying bolus 5-flourouracil as a new treatment of ependymoma that has now entered clinical trial. 9 The integration of cell culture and robotic technologies has made HTS a powerful drug discovery tool, identifying hundreds of lead compounds with potent anticancer cell activity. 10, 11 But further triaging of these compounds for resource-intensive, in vivo testing in mice can be difficult. We reasoned that zebrafish might provide a relatively inexpensive and high-throughput system to triage compounds between HTS and definitive mouse model studies. Zebrafish have proved an excellent tool for studying the biology and treatment of cancer, including human tumor xenografts, but they have not been studied as a host for brain tumors or mouse cancer xenografts. 12, 13 Here we report an efficient system that allows mouse brain tumors to be grown in the brains of zebrafish. These tumors recapitulate the histology of the parent mouse tumor and can be used to test drug efficacy. As large cohorts of zebrafish bearing brain tumors can be generated rapidly and inexpensively, these models may serve as a powerful new tool in the drug development pipeline between HTS and formal efficacy testing in mice.
RESULTS AND DISCUSSION
Establishment of orthotopic mouse brain tumor xenografts in zebrafish Red fluorescence protein (RFP)-expressing tumor cells were isolated from three mouse brain tumor models generated exactly as described previously, 7 including a mouse model of glioblastoma (GBM) generated by transducing Ink4a/Arf −/ − , mouse embryonic neural stem cells (NSC) with an ERBB2-RFP retrovirus (GBM ERBB2-RFP ) and two separate ependymoma models generated from NSC transduced with RTBDN-RFP (EP RTBDN-RFP ) or EPHB2-RFP retroviruses (EP EPHB2-RFP ). We also isolated cells from a new mouse model of choroid plexus carcinoma that we recently developed by transducing the choroid plexus of embryonic Tp53 flx/flx , Rb flx/flx and PTEN flx/flx mice with cre-recombinase-RFP (CPC RFP , unpublished). As a first step to test whether mouse brain tumors can grow orthotopically in zebrafish, we implanted 10 zebrafish with 2 × 10 into the cerebrum of anesthetized, 30-day-old, dexamethasoneimmunosuppressed, zebrafish. Ten control fish were similarly implanted with RFP-only-transduced NSC. Similar amounts of RFP + cells were readily detected by direct intravital fluorescence microscopy (IFM) in all zebrafish brains 24 h following implantation; but no tumor cells were detectable in recipient zebrafish after 3 days and no fish developed tumors (data not shown).
We reasoned that the marked difference in body temperature between mice (37°C) and zebrafish (~28°C) might account for the failed engraftment of tumors. Therefore, we conditioned freshly isolated cultures of mouse tumors (or control NSC RFP ) to grow at 34°C by reducing the temperature of cultured cells by 0.75°C per week for 4 weeks (Figures 1a and b) . Similarly, we acclimatized zebrafish to an ambient temperature of 34°C by increasing their water temperature by 1°C per day for 6 days ( Figure 1c Zebrafish brain tumors recapitulate the histology of the parent tumor and metastasize through the central nervous system As an initial test of the fidelity of our brain tumor xenografts, we reviewed the histology and immunophenotype of all tumors (Figure 3a) . Each mouse brain tumor retained its hallmark morphological features when xenografted into zebrafish brains. EP RTBDN-RFP and EP EPHB2-RFP tumors in both mouse and zebrafish contained pseudorosettes and were glial fibrillary acidic protein immunoreactive. GBM ERBB2-RFP tumors in both species displayed cellular pleomorphism, had high mitotic rates (indicated by robust Ki67 nuclear immunoreactivity) and were intensely ERBB2 and glial fibrillary acidic protein immunoreactive. Finally, CPC RFP tumors displayed a typical epithelioid morphology and expressed transthyretin receptor that is highly restricted to normal and malignant choroid plexus 14 ( Figure 3a ). Brain tumors have a propensity to disseminate through the central nervous system (CNS). Therefore, to test whether zebrafish xenografts also metastasize, we generated cohorts of zebrafish implanted with EP RTBDN-RFP , GBM ERBB2-RFP or CPC RFP cells and monitored the spines of each animal using daily IFM (Figure 3b ). 5.3% (n = 5/94), 11.1% (n = 3/27) and 23.1% (n = 3/13) of zebrafish bearing GBM ERBB2-RFP , CPC RFP and EP RTBDN-RFP tumors, respectively, developed RFP + masses along the spinal axis that were distinct from the main implanted tumor. In each case, spinal masses were undetectable immediately following cell implantation, but developed 1-2 days post implantation. Histologic analyses of the complete CNS of fish confirmed that these masses were independent, distant deposits of tumor rather than direct extensions of the main tumor mass (Figure 3b ). Thus, implanted mouse brain tumors disseminate through the CNS of zebrafish and IFM of these tumors may serve as a useful tool for studying brain tumor metastasis in vivo.
Xenografted mouse brain tumors recruit zebrafish CNS vasculature The recruitment of normal blood vessels by cancer cells represents a critical step in tumorigenesis and metastasis.
15 Fli1:enhanced green fluorescence protein (eGFP) transgenic zebrafish that express eGFP specifically in endothelial cells 16 have been used effectively to study angiogenesis in peripheral solid tumor xenografts. 17 Therefore, to test whether mouse brain tumor cells are competent to induce angiogenesis in zebrafish, we generated EP RTBDN-RFP and GBM ERBB2-RFP tumors in Fli1:eGFP fish. Dual immunofluorescence of tumor sections confirmed that all RFP + mouse brain tumors effectively recruited an eGFP + zebrafish vasculature ( Figure 3c ). In contrast to the uniform, regularly spaced and non-tortuous vessels in normal brain, eGFP + blood vessels in mouse xenografts were frequently branched, highly variable in size and tortuous ( Figure 3c ). Thus, mouse brain tumors implanted in zebrafish recruit host vasculature. As fluorescent tumor cells and blood vessels can be imaged by IFM in live animals, this system holds great promise to study brain tumor angiogenesis in vivo.
Mouse gliomas retain the transcriptome of their parent tumor in zebrafish To test more comprehensively whether our xenografts recapitulate the biology of the corresponding parent mouse brain tumor, we used Affymetrix M430 microarrays (Santa Clara, CA, USA) to compare the transcriptomes of GBM ERBB2-RFP , EP RTBDN-RFP and CPC RFP tumors growing in both species. Unsupervised, hierarchical clustering of tumor transcriptomes confirmed that, regardless of host species, samples of the same tumor type are related to each other, but are distinct from other tumors (Figure 3d ). To test whether the transcriptome of any given tumor type grown in mice correlates with the transcriptome of the same tumor type grown in zebrafish, we used our recently developed the agreement of differential expression (AGDEX) algorithm that estimates the degree of similarity between transcriptomes derived from different tissues. 7, 18 A positive AGDEX score indicates a positive correlation in transcriptome between compared tissues; the significance of this correlation is assigned a permuted P-value that controls for false discovery. All three tumor types displayed positive AGDEX scores, indicating that the mouse and zebrafish brain tumor transcriptomes are positively related (Figure 3e ). GBM ERBB2-RFP correlated particularly closely with the parent mouse tumor, suggesting that zebrafish xenografts of this tumor are especially faithful reproductions of the parent tumor (AGDEX score 0.24, permuted P = 0.02; Figure 3e ).
Brain tumor xenografts in zebrafish can be used as a preclinical drug development tool As GBM ERBB2-RFP xenografts most closely recapitulated the histology and transcriptome of their parent mouse tumors, we used this model to test our system as a preclinical drug development tool. Current cancer chemotherapies can be broadly divided into nonspecific cytotoxic drugs and small molecule inhibitors of specific tumorigenic proteins. We selected one drug each from these two classes that have known activity against human GBM: the cytotoxic antimetabolite 5-fluorouracil (5-FU) 19 and tyrosine kinase inhibitor erlotinib 20 that targets ERBB2, which is mutated in human GBM 21 and drives GBM ERBB2-RFP . First, we confirmed that GBM ERBB2-RFP cells are sensitive to 5-FU and erlotinib with an effective concentration to inhibit growth by 50% of 0.34 and 0.21 μM, respectively (Figures 4a and b) . Next, 28 adult zebrafish were implanted with GBM ERBB2-RFP cells exactly as were killed using 0.04% tricaine and fixed in 4% paraformaldehyde overnight. Zebrafish were then decalcified using 0.5 M EDTA (AMRESCO, Solon, OH, USA) for 5 days, rinsed in phosphate-buffered saline, dehydrated and paraffin wax embedded. Sections (5 μm) were stained using hematoxylin and eosin (H&E) or subjected to standard immunohistochemistry using the indicated primary antibodies (GFAP 1:500, Dako rabbit polyclonal Z0334, Carpenteria, CA, USA; ERBB2 1:40, Vector mouse monoclonal VP-C380; Ki67 1:1000, Vector rabbit polyclonal vp-K451). Transthyretin receptor expression was visualized by in situ hybridization using a full-length transthyretin receptor cRNA template (BC032069, generous gift of Dr Edwin Monuki). Paraffin sections were treated with RNAzip (Ambion, Austin, TX, USA) and de-waxed to water. Probe hybridization was performed at 60°C overnight in standard hybridization buffer. Sections of the same tumors growing in mouse brains were analyzed in parallel for comparison. Arrows in EP RTBDN-RFP H&E and glial fibrillary acidic protein (GFAP) mark pseudorosettes and GFAP + tumor cells, respectively. Dotted line in bottom right GBM ERBB2-RFP H&E demarcates tumor invading normal brain. Arrow indicates mitotic tumor cells (scale bars = 15 μm). (b) Zebrafish were implanted with the indicated tumors, and the entire dorsal brain and spine imaged daily exactly as described in Figures 1 and 2 . Arrows in H&E of EP RTBDN-RFP tumors mark individual metastatic deposits. Pie charts report the proportion of zebrafish in which the indicated tumors metastasized. (c) Fli1:eGFP zebrafish harboring tumors were killed fixed and decalcified as described above. Brains containing tumor were then cryoprotected in 30% sucrose for 2 days and frozen in tissue-freezing media (Triangle Biomedical Sciences, Durham, NC, USA). Sections (12 μm) were counter stained using DAPI-containing hard set mounting media and imaged by confocal microscopy with 488 and 594 nm filters. (d) Total RNA was extracted from the indicated brain tumors grown in mouse and zebrafish brains. Microarray gene expression profiles were generated using Affymetrix 430v2 arrays and subject to unsupervised hierarchical clustering exactly as described. 7 Transcriptomes of each tumor type grown in mouse and human brains were directly compared using the AGDEX algorithm exactly as described was used. 7 described above and imaged using IFM to confirm the presence of RFP + tumor cells. Zebrafish were then randomly assigned to one of four treatment groups: vehicle control (n = 9, 5-FU; n = 5, erlotinib); 5-FU (n = 8); or erlotinib (n = 6). Erlotinib is water insoluble, and was therefore delivered by oral gavage as described previously. 22 Briefly, 10 μl of a 5% dimethylsulfoxide solution containing an equivalent of 200 mg/kg erlotinib was delivered via a p10 pipette tip inserted into the oral cavity of anaesthetized fish so that the tip was positioned adjacent to the gills. We showed previously that this dose blocks ERBB2 signaling in brain tumors in . Zebrafish brain tumor models can be used for preclinical drug testing. (a) Single cell suspensions of 750 GBM ERBB2-RFP tumor cells were seeded into each well of a 96-well plate in a neurobasal medium exactly as described. 7 Twenty-four hours later cells were dosed with the indicated concentrations of (a) 5-FU, (b) erlotinib or DMSO vehicle control and incubated for a further 72 h. Percent cell survival relative to DMSO-only controls was then determined in each well using the Cell Titer Glo reagent (Promega, San Luis Obispo, CA, USA) and Envision plate reader (Perkin-Elmer, Waltham, MA, USA). Assays were performed in independent triplicates. (c) Zebrafish harboring GBM ERBB2-RFP tumors were established exactly as described in Figure 1 . After 24 h, zebrafish were treated with addition of 5-FU or vehicle (control) to the tank water (top), or vehicle (control) or erlotinib by oral gavage on 2 consecutive days. All zebrafish were imaged exactly as described in Figure 2 mice. 23 The 'erlotinib group' was dosed once per day on 2 consecutive days. Control fish were treated by oral gavage of vehicle only (5% dimethylsulfoxide). 5-FU was administered to zebrafish by adding the drug directly to tank water. We first determined the maximum-tolerated dose of 5-FU by adding increasing concentrations of drug to the tank water of non-tumorbearing fish (data not shown). The '5-FU group' were then treated at this maximum-tolerated dose (4.7 mM) on 2 consecutive days. Five control zebrafish received dimethylsulfoxide only. Tumor development was measured in all zebrafish by IFM. GBM ERBB2-RFP tumors in zebrafish were highly sensitive to 5-FU therapy, displaying a~50% reduction in tumor size relative to baseline, whereas tumors in vehicle-treated fish doubled in size over the same time period (Figures 4c and d; P o0.0001) . Erlotinib also inhibited brain tumor growth relative to control treatment, although this effect was less significant than that of 5-FU (Figures 4c and d; P o 0.01) .
Finally, as erlotinib inhibits the ERBB2 tyrosine kinase that drives GBM ERBB2-RFP tumors, we used phospho-specific immunohistochemistry to test whether the drug inhibited ERBB2 signaling brain tumors in zebrafish (Figure 4e) . Intense, membrane and cytoplasmic pERBB2
Y1248 immunoreactivity was readily detected in GBM ERBB2-RFP cells in the brains of three independent, vehicletreated fish. In stark contrast, pERBB2
Y1248 immunoreactivity was virtually undetectable in GBM ERBB2-RFP tumors 3 days following the onset of erlotinib therapy (Figure 4e ). Thus, erlotinib effectively inhibits ERBB2 signaling in tumor cells in the zebrafish brain.
We report the first orthotopic models of mouse brain tumors in adult zebrafish. All models recapitulate the histology of their parent tumor. In addition, our glioma model retained a similar gene expression profile to its parent tumor. We further show that metastasis can be imaged in live zebrafish. Imaging of metastasis and other cellular processes in mice is challenging, in large part because existing fluorescence, bioluminescence and radiological imaging of mice have limited resolution. The translucency, small size and ease of husbandry of zebrafish renders them useful for studying hematopoietic and solid malignancies in peripheral tissues in vivo. 12, 13 Our demonstration that tumor dissemination can also be visualized in the zebrafish CNS could greatly enhance understanding of the biology and treatment of brain metastasis. This is especially important as primary brain tumors kill patients by direct or metastatic invasion of the nervous system, 24 and brain metastasis of peripheral solid cancers are a major cause of morbidity and mortality. 25 Our zebrafish system also allows preclinical testing of potential new brain tumor therapies. Tumor-bearing zebrafish embryos are an established system for the conduct of chemical, genetic and therapeutic screens of cancer. 12, 13, [26] [27] [28] Indeed, drug screens against melanoma in zebrafish embryos have led directly to human clinical trials of the dihydroorotate dehydrogenase inhibitor, leflunomide. As zebrafish embryos can be maintained and treated in multi-well plates, they are a valuable whole-organism system for conducting chemical screens. 26 However, the bathing of embryos in drug solution does not accurately model clinical drug dosing and it is unclear whether tumors growing in developing or mature tissues are equivalently responsive to drugs. Our system allows for testing of drugs against brain tumors growing in the adult brain. We further show that oral gavage (erlotinib) or direct tank water administration (5-FU) of drug can be used to treat tumors in this system.
We are currently working to refine our zebrafish brain tumor models. Adult zebrafish need to be immunosuppressed to accept tumor xenografts, as there are no widely available immunodeficient mutants. Current approaches to immunosuppress zebrafish include chemical or radiation immunoablation. 13 However, these treatments can result in unwanted morbidity and mortality, reducing the efficiency of the experimental system. Therefore, we are investigating whether recently described immunodeficient but viable mutant strains, for example, Rag1
− / − , 29 can accept tumor xenografts without the need for exogenous immunosuppression. Additional mutant strains may also improve the utility of our model system. The relative translucency of zebrafish facilitates transcranial fluorescence imaging of brain tumors; however, the resolution of this imaging could be increased markedly in mutants that lack melanophores or iridiophores, for example, Casper mutant. 30 Indeed, although reproducible growth was detected in our tumor implants, inter-tumoral variability in tumor growth was noted. This might reflect, in part, difficulties in detecting deepseated fluorescent tumor cells through a translucent cranium. Thus, mutant fish may improve the resolution and sensitivity of our imaging system.
Although our models hold promise to advance the treatment of brain tumors, several questions need to be addressed before zebrafish can be formally integrated into the drug development pipeline for these diseases. In particular, the degree to which drug efficacy in zebrafish predicts activity in mice and humans remains to be determined. It will be especially important to determine differences in the pharmacokinetics of drugs among zebrafish, mice and humans. Relatively little is known about the pharmacokinetics of most drugs in zebrafish. If our fish model is to effectively triage drugs between HTS and mouse models, then it will be important to ensure that promising agents are not rejected because of unfavorable, but species-specific, pharmacokinetic profiles in zebrafish. Ongoing parallel studies of zebrafish and mouse systems should answer these important questions.
